Essential Premium

Third Point Inches Lower in November as Magnificent Seven Stumble

Dan Loeb’s multistrategy fund saw only a slight dip last month, but the drivers behind the loss give a glimpse of its positioning heading into year-end.

Private Equity Fundraising Remains Glum, Four Years On

Secondaries remain a bright spot, while PE and venture capital funds face another down year.

Sponsored

The Five Ds of 2025

RA Capital Doubles Down on Private Deals as Year-End Frenzy Builds

The biopharma specialist hedge fund is on track for its busiest quarter yet, pouring money into startups while launching a new vehicle focused on planetary health.

Related Content

How Third Point Fared After Increasing Bets on Stocks

Stephen Taub

In the Hunt for Fraud, the Red Flags Start With the Auditor

Richard Teitelbaum

Hedge Funds Cash in on Rare IPO

Stephen Taub

1270 Avenue of the Americas, Suite 1100

New York, NY 10020

 

© Institutional Investor, LLC. All material subject to strictly enforced copyright laws. Please read our Terms and Conditions and Privacy Policy before using the site. Institutional Investor is part of Delinian.

 

| Unsubscribe

LinkedIn
X (Twitter)
Bluesky
Instagram